FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998050921> ?p ?o ?g. }

• W1998050921 endingPage "342" @default.
• W1998050921 startingPage "335" @default.
• W1998050921 abstract "Buprenorphine (BUP), a synthetic opioid analgesic, is frequently abused alone, and in association with benzodiazepines. Fatalities involving buprenorphine alone seem very unusual while its association with benzodiazepines, such as flunitrazepam (FNZ), has been reported to result in severe respiratory depression and death. The quantitative relationship between these drugs remain, however, uncertain. Our objective was to develop an analytical method that could be used as a means to study and explore, in animals, the toxicity and pharmacological interaction mechanisms between buprenorphine, flunitrazepam and their active metabolites. A procedure based on gas chromatography-mass spectrometry (GC-MS) is described for the simultaneous analysis of buprenorphine, norbuprenorphine (NBUP), flunitrazepam, N-desmethylflunitrazepam (N-DMFNZ) and 7-aminoflunitrazepam (7-AFNZ) in rat plasma. The method was set up and adapted for the analysis of small plasma samples taken from rats. Plasma samples were extracted by liquid-liquid extraction using Toxi-tubes A. Extracted compounds were derivatized with N,O-bis-(trimethylsilyl)trifluoroacetamide (BSTFA), using trimethylchlorosilane (TMCS) as a catalyst. They were then separated by GC on a crosslinked 5% phenyl-methylpolysiloxane analytical column and determined by a quadrupole mass spectrometer detector operated under selected ion monitoring mode. Excellent linearity was found between 0.125 and 25 ng/microl plasma for BUP, 0.125 and 12.5 ng/microl for NBUP and N-DMFNZ, 0.125 and 5 ng/microl for FNZ, and between 0.025 and 50 ng/microl for 7-AFNZ. The limit of quantification was 0.025 ng/microl plasma for 7-AFNZ and 0.125 ng/microl for the four other compounds. A good reproducibility (intra-assay CV=0.32-11.69%; inter-assay CV=0.63-9.55%) and accuracy (intra-assay error=2.58-12.73%; inter-assay error=0.83-11.07%) were attained. Recoveries were 71, 67 and 81%, for BUP, FNZ and N-DMFNZ, respectively, and 51% for NBUP and 7-AFNZ, with CV ranging from 5.4 to 13.9%, and were concentration-independent. The GC-MS method was successfully applied to the pharmacokinetic study of BUP, NBUP, FNZ, DMFNZ and 7-AFNZ in rats, after administration of BUP and FNZ." @default.
• W1998050921 created "2016-06-24" @default.
• W1998050921 creator A5007110646 @default.
• W1998050921 creator A5009299826 @default.
• W1998050921 creator A5021744927 @default.
• W1998050921 creator A5025325607 @default.
• W1998050921 creator A5045782776 @default.
• W1998050921 creator A5073590802 @default.
• W1998050921 creator A5080617055 @default.
• W1998050921 creator A5082013510 @default.
• W1998050921 date "2004-08-01" @default.
• W1998050921 modified "2023-10-18" @default.
• W1998050921 title "Development and validation of a gas chromatography–mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study" @default.
• W1998050921 cites W1515542254 @default.
• W1998050921 cites W172436023 @default.
• W1998050921 cites W194322098 @default.
• W1998050921 cites W1987627204 @default.
• W1998050921 cites W1988215175 @default.
• W1998050921 cites W1988811362 @default.
• W1998050921 cites W1990905986 @default.
• W1998050921 cites W1992394609 @default.
• W1998050921 cites W2000520053 @default.
• W1998050921 cites W2006323464 @default.
• W1998050921 cites W2010835452 @default.
• W1998050921 cites W2025263887 @default.
• W1998050921 cites W2033463451 @default.
• W1998050921 cites W2033991790 @default.
• W1998050921 cites W2034574329 @default.
• W1998050921 cites W2041072004 @default.
• W1998050921 cites W2052638576 @default.
• W1998050921 cites W2064611696 @default.
• W1998050921 cites W2067578746 @default.
• W1998050921 cites W2071509183 @default.
• W1998050921 cites W2077563362 @default.
• W1998050921 cites W2094604766 @default.
• W1998050921 cites W2101643540 @default.
• W1998050921 cites W2107570847 @default.
• W1998050921 cites W2108706950 @default.
• W1998050921 cites W2108978934 @default.
• W1998050921 cites W2110436248 @default.
• W1998050921 cites W2127383228 @default.
• W1998050921 cites W2142355747 @default.
• W1998050921 cites W2143055542 @default.
• W1998050921 cites W2144525027 @default.
• W1998050921 cites W2153399020 @default.
• W1998050921 cites W2162010569 @default.
• W1998050921 cites W2164989466 @default.
• W1998050921 cites W2170567881 @default.
• W1998050921 cites W4300702859 @default.
• W1998050921 doi "https://doi.org/10.1016/j.jchromb.2004.04.029" @default.
• W1998050921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15203048" @default.
• W1998050921 hasPublicationYear "2004" @default.
• W1998050921 type Work @default.
• W1998050921 sameAs 1998050921 @default.
• W1998050921 citedByCount "27" @default.
• W1998050921 countsByYear W19980509212016 @default.
• W1998050921 countsByYear W19980509212020 @default.
• W1998050921 countsByYear W19980509212021 @default.
• W1998050921 countsByYear W19980509212023 @default.
• W1998050921 crossrefType "journal-article" @default.
• W1998050921 hasAuthorship W1998050921A5007110646 @default.
• W1998050921 hasAuthorship W1998050921A5009299826 @default.
• W1998050921 hasAuthorship W1998050921A5021744927 @default.
• W1998050921 hasAuthorship W1998050921A5025325607 @default.
• W1998050921 hasAuthorship W1998050921A5045782776 @default.
• W1998050921 hasAuthorship W1998050921A5073590802 @default.
• W1998050921 hasAuthorship W1998050921A5080617055 @default.
• W1998050921 hasAuthorship W1998050921A5082013510 @default.
• W1998050921 hasConcept C119128265 @default.
• W1998050921 hasConcept C123460561 @default.
• W1998050921 hasConcept C162356407 @default.
• W1998050921 hasConcept C170493617 @default.
• W1998050921 hasConcept C179302884 @default.
• W1998050921 hasConcept C185592680 @default.
• W1998050921 hasConcept C205345274 @default.
• W1998050921 hasConcept C2777477808 @default.
• W1998050921 hasConcept C2778173252 @default.
• W1998050921 hasConcept C2778949969 @default.
• W1998050921 hasConcept C2781063702 @default.
• W1998050921 hasConcept C2781442855 @default.
• W1998050921 hasConcept C43617362 @default.
• W1998050921 hasConcept C55493867 @default.
• W1998050921 hasConceptScore W1998050921C119128265 @default.
• W1998050921 hasConceptScore W1998050921C123460561 @default.
• W1998050921 hasConceptScore W1998050921C162356407 @default.
• W1998050921 hasConceptScore W1998050921C170493617 @default.
• W1998050921 hasConceptScore W1998050921C179302884 @default.
• W1998050921 hasConceptScore W1998050921C185592680 @default.
• W1998050921 hasConceptScore W1998050921C205345274 @default.
• W1998050921 hasConceptScore W1998050921C2777477808 @default.
• W1998050921 hasConceptScore W1998050921C2778173252 @default.
• W1998050921 hasConceptScore W1998050921C2778949969 @default.
• W1998050921 hasConceptScore W1998050921C2781063702 @default.
• W1998050921 hasConceptScore W1998050921C2781442855 @default.
• W1998050921 hasConceptScore W1998050921C43617362 @default.
• W1998050921 hasConceptScore W1998050921C55493867 @default.
• W1998050921 hasIssue "2" @default.
• W1998050921 hasLocation W19980509211 @default.

• next